Eliglustat tartrate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for eliglustat tartrate and what is the scope of freedom to operate?
Eliglustat tartrate
is the generic ingredient in two branded drugs marketed by Genzyme Corp, Aizant, Apotex, Dr Reddys, Teva Pharms Usa Inc, and Upsher Smith Labs, and is included in six NDAs. There are four patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.Eliglustat tartrate has one hundred and sixty-two patent family members in forty-four countries.
There are six drug master file entries for eliglustat tartrate. One supplier is listed for this compound.
Summary for eliglustat tartrate
International Patents: | 162 |
US Patents: | 4 |
Tradenames: | 2 |
Applicants: | 6 |
NDAs: | 6 |
Drug Master File Entries: | 6 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 44 |
Clinical Trials: | 6 |
Patent Applications: | 137 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for eliglustat tartrate |
DailyMed Link: | eliglustat tartrate at DailyMed |
Recent Clinical Trials for eliglustat tartrate
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Sanofi | Phase 1 |
Genzyme, a Sanofi Company | Phase 1 |
Genzyme, a Sanofi Company | Phase 3 |
Pharmacology for eliglustat tartrate
Drug Class | Glucosylceramide Synthase Inhibitor |
Mechanism of Action | Cytochrome P450 2D6 Inhibitors Glucosylceramide Synthase Inhibitors P-Glycoprotein Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for eliglustat tartrate
Paragraph IV (Patent) Challenges for ELIGLUSTAT TARTRATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CERDELGA | Capsules | eliglustat tartrate | 84 mg | 205494 | 6 | 2018-08-20 |
US Patents and Regulatory Information for eliglustat tartrate
Expired US Patents for eliglustat tartrate
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Genzyme Corp | CERDELGA | eliglustat tartrate | CAPSULE;ORAL | 205494-001 | Aug 19, 2014 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for eliglustat tartrate
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Argentina | 079152 | INHIBIDORES DE GLUCOSILCERAMIDA SINTASA | ⤷ Sign Up |
Singapore | 10201800136Q | AN AMORPHOUS AND A CRYSTALLINE FORM OF GENZ 112638 HEMITARTRATE AS INHIBITOR OF GLUCOSYLCERAMIDE SYNTHASE | ⤷ Sign Up |
Denmark | 2796457 | ⤷ Sign Up | |
Poland | 3599237 | ⤷ Sign Up | |
Brazil | 122015016314 | método para preparar um composto acíclico, método para preparar um composto amina, método de preparar um composto como esfingosina e método para preparar um composto como ceramida | ⤷ Sign Up |
European Patent Office | 1409467 | UN INHIBITEUR DE N-ACYLSPHINGOSINE GLYCOSYLTRANSFERASE (A N-ACYLSPHINGOSINE GLUCOSYLTRANSFERASE INHIBITOR) | ⤷ Sign Up |
China | 105777707 | 作为葡糖神经酰胺合酶的抑制剂的无定型和结晶形式的Genz 112638半酒石酸盐 (An amorphous and a crystalline form of Genz 112638 hemitartrat as inhibitor of glucosylceramide synthase) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for eliglustat tartrate
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1409467 | 37/2015 | Austria | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
1409467 | 1590029-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121 |
1409467 | 132016000023075 | Italy | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, OPZIONALMENTE NELLA FORMA DI UN SALE FARMACOLOGICAMENTE ACCETTABILE(CERDELGA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/14/974, 20150119 |
1409467 | 15C0036 | France | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT,EVENTUELLEMENT SOUS FORME D'UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
1409467 | CR 2015 00035 | Denmark | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, EVENTUELT I FORM AF ET FYSIOLOGISK ACCEPTABELT SALT, HERUNDER ELIGLUSTAT (SOM TARTRAT); REG. NO/DATE: EU/1/14/974 20150119 |
1409467 | 2015/027 | Ireland | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
1409467 | 122015000051 | Germany | ⤷ Sign Up | PRODUCT NAME: ELIGLUSTAT; REGISTRATION NO/DATE: EU/1/14/974 20150119 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.